中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 11
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(11): 2505-2509

Drug-induced liver injury: Advances and confusions in treatment

DOI: 10.3969/j.issn.1001-5256.2021.11.001

  • Department of Gastroenterology, Tongji Hospital Affiliated to Tongji University, Shanghai 200065, China

Research funding:

National Natural Science Foundation of China (81670571);

National Natural Science Foundation of China (81820108006);

Shanghai Clinical Key Specialty Project (SHSLCZDZK06801);

Clinical Research Plan of SHDC (SHDC2020CR2030B)

  • Received Date: 2021-08-30
  • Accepted Date: 2021-08-30
  • Published Date: 2021-11-20
    Abstract
  • Drug-induced liver injury (DILI) is one of the most common and serious adverse drug reactions and can lead to acute liver failure and even death in severe cases. The pathogenesis of DILI has not been fully clarified, and there is significant individual difference. There is no effective treatment for advanced DILI except liver transplantation, and therefore, early diagnosis and precise treatment are of particular importance. This article reviews the important research advances and difficult issues in the treatment of DILI in recent years.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [2]
    BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425, 1425. e1-3; quiz e19-20. DOI: 10.1053/j.gastro.2013.02.006.
    [3]
    BJÖRNSSON ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury[J]. Semin Liver Dis, 2014, 34(2): 115-122. DOI: 10.1055/s-0034-1375953.
    [4]
    SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11. DOI: 10.1053/j.gastro.2019.02.002.
    [5]
    HUNT CM, PAPAY JI, STANULOVIC V, et al. Drug rechallenge following drug-induced liver injury[J]. Hepatology, 2017, 66(2): 646-654. DOI: 10.1002/hep.29152.
    [6]
    XU CF, JOHNSON T, WANG X, et al. HLA-B*57: 01 Confers Susceptibility to pazopanib-associated liver injury in patients with cancer[J]. Clin Cancer Res, 2016, 22(6): 1371-1377. DOI: 10.1158/1078-0432.CCR-15-2044.
    [7]
    WATKINS PB, LEWIS JH, KAPLOWITZ N, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: Analysis of clinical trials database[J]. Drug Saf, 2015, 38(11): 1103-1113. DOI: 10.1007/s40264-015-0327-3.
    [8]
    BANIASADI S, EFTEKHARI P, TABARSI P, et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity[J]. Eur J Gastroenterol Hepatol, 2010, 22(10): 1235-1238. DOI: 10.1097/MEG.0b013e32833aa11b.
    [9]
    KNOWLES SR, SHAPIRO LE, SHEAR NH. Anticonvulsant hypersensitivity syndrome: Incidence, prevention and management[J]. Drug Saf, 1999, 21(6): 489-501. DOI: 10.2165/00002018-199921060-00005.
    [10]
    BORLAK J, van BÖMMEL F, BERG T. N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury[J]. Liver Int, 2018, 38(2): 365-376. DOI: 10.1111/liv.13538.
    [11]
    KAN M, HIMES BE. Insights into glucocorticoid responses derived from omics studies[J]. Pharmacol Ther, 2021, 218: 107674. DOI: 10.1016/j.pharmthera.2020.107674.
    [12]
    DARNELL EP, MOORADIAN MJ, BARUCH EN, et al. Immune-related adverse events (irAEs): Diagnosis, management, and clinical pearls[J]. Curr Oncol Rep, 2020, 22(4): 39. DOI: 10.1007/s11912-020-0897-9.
    [13]
    NISHIDA N, KUDO M. Liver damage related to immune checkpoint inhibitors[J]. Hepatol Int, 2019, 13(3): 248-252. DOI: 10.1007/s12072-018-9921-7.
    [14]
    TUJIOS SR, LEE WM. Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy[J]. Liver Int, 2018, 38(1): 6-14. DOI: 10.1111/liv.13535.
    [15]
    WAN YM, WU JF, LI YH, et al. Prednisone is not beneficial for the treatment of severe drug-induced liver injury: An observational study (STROBE compliant)[J]. Medicine (Baltimore), 2019, 98(26): e15886. DOI: 10.1097/MD.0000000000015886.
    [16]
    MAO YM, ZENG MD, CHEN Y, Et al. Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: A randomized, double-blind, multi-doses, active drug controlled, multi-center study[J]. Chin J Hepatol, 2009, 17(11): 847-851. DOI: 10.3760/cma.j.issn.1007-3418.2009.11.013.

    茅益民, 曾民德, 陈勇, 等. 异甘草酸镁治疗ALT升高的慢性肝病的多中心、随机、双盲、多剂量、阳性药物平行对照临床研究[J]. 中华肝脏病杂志, 2009, 17(11): 847-851. DOI: 10.3760/cma.j.issn.1007-3418.2009.11.013.
    [17]
    WANG Y, WANG Z, GAO M, et al. Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: A phase Ⅱ trial[J]. Liver Int, 2019, 39(11): 2102-2111. DOI: 10.1111/liv.14204.
    [18]
    ZHAO Z, BAO L, YU X, et al. Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: A case report[J]. Medicine (Baltimore), 2017, 96(36): e8009. DOI: 10.1097/MD.0000000000008009.
    [19]
    GU J, TANG SJ, TAN SY, et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury[J]. Int J Clin Exp Med, 2015, 8(3): 4320-4327.
    [20]
    LUANGCHOSIRI C, THAKKINSTIAN A, CHITPHUK S, et al. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury[J]. BMC Complement Altern Med, 2015, 15: 334. DOI: 10.1186/s12906-015-0861-7.
    [21]
    ASGARSHIRAZI M, SHARIAT M, SHEIKH M. Comparison of efficacy of folic acid and silymarin in the management of antiepileptic drug induced liver injury: A randomized clinical trial[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(3): 296-302. DOI: 10.1016/s1499-3872(16)60142-x.
    [22]
    DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines[J]. Hepatol Int, 2021, 15(2): 258-282. DOI: 10.1007/s12072-021-10144-3.
    [23]
    NAIQIONG W, LIANSHENG W, ZHANYING H, et al. A multicenter and randomized controlled trial of bicyclol in the treatment of statin-induced liver injury[J]. Med Sci Monit, 2017, 23: 5760-5766. DOI: 10.12659/msm.904090.
    [24]
    SALIBA F, CAMUS C, DURAND F, et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: A randomized, controlled trial[J]. Ann Intern Med, 2013, 159(8): 522-531. DOI: 10.7326/0003-4819-159-8-201310150-00005.
    [25]
    LARSEN FS, SCHMIDT LE, BERNSMEIER C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial[J]. J Hepatol, 2016, 64(1): 69-78. DOI: 10.1016/j.jhep.2015.08.018.
    [26]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. DOI: 10.1016/j.jhep.2019.02.014.
    [27]
    HILLMAN L, GOTTFRIED M, WHITSETT M, et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury[J]. Am J Gastroenterol, 2016, 111(7): 958-965. DOI: 10.1038/ajg.2016.114.
    [28]
    ADAM R, KARAM V, CAILLIEZ V, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation[J]. Transpl Int, 2018, 31(12): 1293-1317. DOI: 10.1111/tri.13358.
    [29]
    WANG J, MA Z, NIU M, et al. Evidence chain-based causality identification in herb-induced liver injury: Exemplification of a well-known liver-restorative herb Polygonum multiflorum[J]. Front Med, 2015, 9(4): 457-467. DOI: 10.1007/s11684-015-0417-8.
    [30]
    ZHAO L, WANG Y, ZHANG Y. The potential diagnostic and therapeutic applications of exosomes in drug-induced liver injury[J]. Toxicol Lett, 2021, 337: 68-77. DOI: 10.1016/j.toxlet.2020.11.021.
    [31]
    MOMEN-HERAVI F, BALA S, BUKONG T, et al. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages[J]. Nanomedicine, 2014, 10(7): 1517-1527. DOI: 10.1016/j.nano.2014.03.014.
    [32]
    POSSAMAI LA, MCPHAIL MJ, KHAMRI W, et al. The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity[J]. Liver Int, 2015, 35(3): 764-773. DOI: 10.1111/liv.12689.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (882) PDF downloads(313) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return